Bristol-Myers Squibb 10-Qquarter ended 2026-09-30

Executive Summary

Bristol Myers Squibb sells prescription medicines to healthcare providers and patients, earning revenue from product sales and alliances. It is expanding newer cancer, blood-disorder and specialty medicines to replace products losing patent protection. Q3 revenue rose 6.9% to $13.1B as newer treatments and Eliquis outweighed generic erosion, but licensing charges and higher costs left net earnings slightly lower. The opportunity is a broader replacement portfolio; the threat is that patent losses and pricing pressure arrive faster than new medicines scale, while cash generation has weakened.

What's Happening in the Business

The portfolio transition is advancing unevenly. Camzyos, Breyanzi and Reblozyl delivered strong growth, while intravenous Opdivo declined partly because U.S. use shifted to recently launched injectable Opdivo Qvantig. Eliquis supplied more than the entire company’s net revenue increase, masking steep generic-driven declines in Revlimid and Pomalyst/Imnovid. Its U.S. list-price reduction lowered rebates enough to increase realized prices, illustrating why falling gross sales did not mean falling net revenue.

Bristol Myers Squibb broadened its commercial pipeline with Zenbexus approval in multiple myeloma and expanded indications for Camzyos, Sotyktu and Opdivo. Zenbexus’s full approval depends on confirmation of clinical benefit. Late-stage results also advanced breast- and lung-cancer treatment iza-bren, radiopharmaceutical RYZ101 and myeloma treatment mezigdomide.

External licensing continues to replenish the pipeline. The Hengrui agreement covers 13 early-stage assets, with a $600M upfront payment and a noncancellable $175M anniversary payment recognized in acquired research charges. Manufacturing and radiopharmaceutical facilities support development and commercialization, while management’s expanded productivity actions target ≈$2.0B of annual savings by the end of 2027.

Key Financial Highlights

• Growth drivers: Eliquis generated $4.69B, +25%; Breyanzi $526M, +46%; Camzyos $420M, +42%; and Reblozyl $750M, +22%. Opdivo Qvantig reached $334M vs $67M, partly offsetting Opdivo’s 6.2% decline to $2.37B.
• Generic erosion: Revlimid fell 47% to $303M and Pomalyst/Imnovid fell 81% to $130M. Legacy Portfolio stability therefore reflects Eliquis strength, not stabilization across older medicines.
• Q3 expense pressure: Acquired research and development charges reached $1.56B vs $633M, including Hengrui and a $500M BioNTech anniversary payment. Product costs rose 21%, including a one-time $140M contract-termination charge and higher Eliquis alliance profit sharing.
• Tax support: The Q3 effective tax rate fell to 15% from 30%, reflecting earnings mix and the absence of prior-year tax reserves; this was not operating improvement.
• Cash and funding: 9M rebate and discount balances consumed $3.87B vs providing $1.96B a year earlier, helping explain the divergence from earnings. After $996M of capital spending, FCF was $7.68B. Dividends were $3.86B vs $3.78B; debt carrying value fell 4.9% from year-end to $42.6B.

Risk Assessment

• Patent and pricing exposure: Eliquis’s European Union patents and supplementary protection certificates expire in 11/2026, while Medicare negotiated prices affect Eliquis from 2026, Pomalyst from 2027 and Orencia from 2028, threatening revenue supporting the transition.
• Pipeline and acquisition execution: 9M acquired-research impairments of $830M show that purchased assets can lose value before commercialization; failed trials or approvals would weaken replacement growth.
• Funding commitments: BioNTech anniversary payments of $2.0B through 2028 and the Hengrui anniversary obligation compete with dividends, debt service and development spending as operating cash flow declines.
• Litigation and reimbursement: The revived Celgene contingent-value-rights case heads toward a 01/2028 trial, while patent disputes, unsuccessful litigation over the proposed 340B rebate model and tax appeals create financial uncertainty.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: FY2025 10-K.

What to Watch

• Replacement-product momentum: Growth Portfolio revenue rose 12%. Sustained growth in Camzyos, Breyanzi and Reblozyl, alongside a successful Opdivo Qvantig transition, would strengthen replacement coverage; slowing adoption would expose dependence on Eliquis.
• Eliquis after pricing and patent changes: Revenue rose 25% this quarter. Subsequent filings should reveal whether demand and realized pricing withstand European patent expiry and Medicare pricing, or whether this growth reverses.
• Pipeline conversion: Mezigdomide has a management-reported regulatory decision expected by 5/13/2027, while Zenbexus requires confirmation of clinical benefit. Approvals and adoption would validate pipeline spending; setbacks would weaken replacement prospects.
• Cash recovery and productivity: Operating cash flow fell 29%. Management’s savings program works if cash generation recovers without undermining product launches and research; persistent weakness would tighten funding flexibility.